This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

NICE guidance - mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Mexiletine (Namuscla) is recommended, within its marketing authorisation, as an option for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders (1).

Mexiletine is a class 1b antiarrhythmic medication with a high affinity for muscle sodium channels (2)

In a series of N-of-1 trials of mexiletine vs placebo in patients with nondystrophic myotonia, there was a reduction in mean daily-reported muscle stiffness that was consistent with the treatment effect in a previous randomized clinical trial (3)

  • findings support the efficacy of mexiletine for treatment of nondystrophic myotonia as well as the feasibility of N-of-1 trials for assessing interventions in some chronic rare diseases

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.